202 results match your criteria Journal of Asthma and Allergy [Journal]


Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab.

J Asthma Allergy 2019 5;12:83-90. Epub 2019 Mar 5.

Department of Medical and Surgical Sciences, Institute of Respiratory Diseases, University of Foggia, Foggia, Italy,

Background: Asthma and bronchiectasis are different conditions that frequently coexist. The prevalence of bronchiectasis rises considerably in subjects with severe asthma (25%-51%).

Objective: We evaluated the clinical and biological efficacy of mepolizumab on our pilot population of severe uncontrolled asthmatics with bronchiectasis not related to other pathologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S196200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407514PMC
March 2019
1 Read

Iodixanol nasal solution reduces allergic rhinoconjunctivitis signs and symptoms in Allergen BioCube: a randomized clinical trial.

J Asthma Allergy 2019 1;12:71-81. Epub 2019 Mar 1.

3E Therapeutics Corporation, La Jolla, CA, USA.

Purpose: Allergic rhinitis (AR) affects ~20% of the population worldwide. The objectives of this study were to evaluate the safety and efficacy of iodixanol nasal solution (Nasapaque) for AR treatment, using the Allergen BioCube (ABC), an environmental exposure unit. Iodixanol is a commonly used contrast media agent that shows efficacy on the signs and symptoms of AR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S150251DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400136PMC
March 2019
1 Read

infection as a reversible cause of chronic urticaria.

J Asthma Allergy 2019 26;12:67-69. Epub 2019 Feb 26.

Department of Allergy, Immunology and Respiratory Medicine, Alfred Health, Melbourne, VIC, Australia,

Recurrent urticaria is a frequent presenting complaint in the Allergy Clinic, despite the fact that chronic urticaria is not an IgE-mediated (atopic) condition in most cases. We present four cases assessed over 5 years in our allergy service who were found to have evidence of strongyloidiasis and whose clinical features resolved with standard anti-helminth treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S167292DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396652PMC
February 2019
1 Read

Two vs four puffs of albuterol: does dose change bronchodilator response?

J Asthma Allergy 2019 31;12:59-65. Epub 2019 Jan 31.

Department of Pediatric Pulmonary Medicine, Connecticut Children's Medical Center, Hartford, CT, USA,

Background: Reversible obstruction on spirometry may be used to diagnose asthma. As per 2005 American Thoracic Society (ATS) guidelines, our pulmonary center began using 360 µg (four puffs) of albuterol rather than 180 µg (two puffs) to determine reversibility on spirometry starting in 2009.

Hypothesis: We hypothesized that fewer patients would respond to two puffs of albuterol than four puffs during spirometric testing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S151531DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362946PMC
January 2019
1 Read

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study.

J Asthma Allergy 2019 25;12:43-58. Epub 2019 Jan 25.

Respiratory, US Medical Affairs, GSK, La Jolla, CA, USA.

Purpose: Patients with severe asthma are eligible for asthma-specific biologics as add-on therapies, such as mepolizumab and omalizumab, when optimized controller therapies are unable to control their symptoms. However, few real-world data are available to describe the characteristics and associated economic burden of patients considered to be candidates for mepolizumab or omalizumab therapy.

Methods: This retrospective cohort study investigated patients with asthma (≥12 years of age) identified at the time of first mepolizumab or omalizumab administration (index date) in the MarketScan Commercial Database. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/real-world-characteristics-and-dis
Publisher Site
http://dx.doi.org/10.2147/JAA.S189676DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354698PMC
January 2019
17 Reads

Association of genetic variants with level of asthma control in the Arab population.

J Asthma Allergy 2019 23;12:35-42. Epub 2019 Jan 23.

Hematology Laboratory, Department of Medical Laboratory, King Abdullah University Hospital, Irbid, Jordan.

Background: Rates of asthma in Jordan have been doubled in the past decade, but this increased prevalence was not met with improved asthma control protocols. The aim of the present study was to assess whether there was any significant association between the level of asthma control and certain single-nucleotide polymorphisms (SNPs) in five genes: (; rs1042713 and rs1042714), (; rs1876828, rs242939, and rs242941), (; rs2236647), (, rs1154400), and (; rs2781659). These SNPs were selected based on their involvement in enzymes and receptors that are related to asthma pathways and subsequent response to medication and based on a high degree of linkage disequilibrium. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S186252DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350652PMC
January 2019

Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma.

J Asthma Allergy 2019 23;12:21-33. Epub 2019 Jan 23.

AstraZeneca, Gaithersburg, MD, USA,

Background: Patients with severe, uncontrolled asthma experience debilitating symptoms that result in meaningful reductions to health-related quality of life. Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody that reduces exacerbations and improves asthma symptoms for patients with severe, uncontrolled eosinophilic asthma.

Objective: The objective of this study was to evaluate improvements in daily asthma-related health status outcomes following treatment with benralizumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S190221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350639PMC
January 2019

Clinical profile of predefined asthma phenotypes in a large cohort of UK primary care patients (Clinical Practice Research Datalink).

J Asthma Allergy 2019 8;12:7-19. Epub 2019 Jan 8.

National Heart and Lung Institute, Imperial College, London, UK.

Background: Distinct asthma phenotypes have previously been suggested, including benign asthma, atopic asthma and obese non-eosinophilic asthma. This study aims to establish if these phenotypes can be identified using data recorded in primary care clinical records and reports on patient characteristics and exacerbation frequency.

Methods: A population-based cohort study identified 193,999 asthma patients in UK primary care from 2007 to 2017. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/clinical-profile-of-predefined-ast
Publisher Site
http://dx.doi.org/10.2147/JAA.S182013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329349PMC
January 2019
12 Reads

Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date.

J Asthma Allergy 2019 3;12:1-5. Epub 2019 Jan 3.

Section of Pulmonary, Critical Care, and Sleep, Department of Medicine, Baylor College of Medicine, Houston, TX, USA,

Asthma is a heterogeneous disease, which may be classified into phenotypes and endotypes based on clinical characteristics and molecular mechanisms. The best described endotype of severe asthma is type 2 (T2)-high asthma, characterized by release of inflammatory cytokines by T helper 2 (T2) cells and type 2 innate lymphoid cells cells. Prostaglandin D2 contributes to T2 inflammation through binding of the G-protein-coupled receptor chemoattractant receptor-homologous molecule expressed on T2 cells (CRTH2). Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/spotlight-on-fevipripant-and-its-p
Publisher Site
http://dx.doi.org/10.2147/JAA.S167973DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324611PMC
January 2019
10 Reads

Matched cohort study of therapeutic strategies to prevent preschool wheezing/asthma attacks.

J Asthma Allergy 2018 11;11:309-321. Epub 2018 Dec 11.

Observational and Pragmatic Research Institute Pte Ltd, Singapore, Singapore.

Background: An inhaled corticosteroid (ICS) or leukotriene receptor antagonist (LTRA) may prevent wheezing/asthma attacks in preschoolers with recurrent wheeze when added to short-acting β-agonist (SABA).

Objective: The aim of this historical matched cohort study was to assess the effectiveness of these treatments for preventing wheezing/asthma attacks.

Methods: Electronic medical records from the Optimum Patient Care Research Database were used to characterize a UK preschool population (1-5 years old) with two or more episodes of wheezing during 1 baseline year before first prescription (index date) of ICS or LTRA, or repeat prescription of SABA. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/matched-cohort-study-of-therapeuti
Publisher Site
http://dx.doi.org/10.2147/JAA.S178531DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294169PMC
December 2018
12 Reads

Asia-Pacific Survey of Physicians on Asthma and Allergic Rhinitis (ASPAIR): physician beliefs and practices about diagnosis, assessment, and treatment of coexistent disease.

J Asthma Allergy 2018 11;11:293-307. Epub 2018 Dec 11.

Respiratory, Global Classic & Established Products, GSK, London, UK.

Background: Asthma and allergic rhinitis (AR) frequently coexist, and having both asthma and AR is associated with uncontrolled asthma and a heavier disease burden. The Asia-Pacific Survey of Physicians on Asthma and Allergic Rhinitis (ASPAIR) aimed to assess physicians' perceptions and their management practices for patients with coexistent disease.

Materials And Methods: A total of 1,204 general physicians and pediatricians from six countries in Asia, who routinely treat asthma patients, were interviewed in-person. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S180657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294166PMC
December 2018
2 Reads

Longitudinal association of adiposity with wheezing and atopy at 22 years: the 1993 Birth Cohort, Pelotas, Brazil.

J Asthma Allergy 2018 30;11:283-291. Epub 2018 Nov 30.

Postgraduate Program in Epidemiology, Federal University of Pelotas, Pelotas, RS, Brazil,

Purpose: Asthma is a highly prevalent noncommunicable lung disease. The aim of this study was to evaluate the longitudinal association of obesity/adiposity with wheezing and atopy.

Methods: The population of the study was composed of participants from the 1993 Pelotas (Brazil) Birth Cohort. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S183699DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280885PMC
November 2018
3 Reads

Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial.

J Asthma Allergy 2018 20;11:181-192. Epub 2018 Nov 20.

AstraZeneca, Gaithersburg, MD, USA.

Background And Objectives: Benralizumab is a humanized, afucosylated monoclonal antibody against the IL-5Rα. Initial monthly followed by every-other-month injections result in rapid and nearly complete eosinophil depletion. We evaluated whether three doses of benralizumab modifies antibody response to seasonal influenza vaccination for adolescent/young adult patients with moderate to severe asthma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S172338DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248228PMC
November 2018
1 Read

Non-eosinophilic asthma: current perspectives.

J Asthma Allergy 2018 29;11:267-281. Epub 2018 Oct 29.

Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ).

Although non-eosinophilic asthma (NEA) is not the best known and most prevalent asthma phenotype, its importance cannot be underestimated. NEA is characterized by airway inflammation with the absence of eosinophils, subsequent to activation of non-predominant type 2 immunologic pathways. This phenotype, which possibly includes several not well-defined subphenotypes, is defined by an eosinophil count <2% in sputum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S153097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211579PMC
October 2018
13 Reads

Utility of a thin bronchoscope in facilitating bronchial thermoplasty.

J Asthma Allergy 2018 15;11:261-266. Epub 2018 Oct 15.

Department of Thoracic Medicine, Frankston Hospital, Peninsula Health, Frankston, Melbourne, VIC, Australia,

Background: A significant correlation has been previously demonstrated between the quantum of radiofrequency treatment delivered at bronchial thermoplasty and the degree of improvement in an asthmatic patient's symptoms. The standard bronchoscope used for bronchial thermoplasty has an outer diameter of 4.8 mm at the distal tip. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/utility-of-a-thin-bronchoscope-in-
Publisher Site
http://dx.doi.org/10.2147/JAA.S179359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198870PMC
October 2018
18 Reads

Diagnosis of fish and shellfish allergies.

J Asthma Allergy 2018 8;11:247-260. Epub 2018 Oct 8.

Division of Rheumatology, Allergy and Clinical Immunology, School of Medicine, University of California Davis, Davis, CA, USA,

Seafood allergy is a hypersensitive disorder with increasing prevalence worldwide. Effective and accurate diagnostic workup for seafood allergy is essential for clinicians and patients. Parvalbumin and tropomyosin are the most common fish and shellfish allergens, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S142476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181092PMC
October 2018
2 Reads

Erratum: Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis [Erratum].

Authors:

J Asthma Allergy 2018 13;11:245. Epub 2018 Sep 13.

[This corrects the article on p. 101 in vol. 11, PMID: 29950869. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S180123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143644PMC
September 2018
3 Reads

Nasopharyngeal isolates and their clinical impact on young children with asthma: a pilot study.

J Asthma Allergy 2018 12;11:233-243. Epub 2018 Sep 12.

Department of Pediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates,

Introduction: Respiratory infections have significant effects on childhood asthma. Viral respiratory infections, such as rhinovirus and respiratory syncytial virus are likely to be important in the development and exacerbation of asthma. In this study, we investigated the nasopharyngeal colonization in children with asthma to determine the prevalence of pathogens and their contribution to respiratory symptoms and airway resistance during winter. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/nasopharyngeal-isolates-and-their-
Publisher Site
http://dx.doi.org/10.2147/JAA.S169966DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140756PMC
September 2018
11 Reads

Rupatadine oral solution for 2-5-year-old children with allergic rhinitis: a safety, open-label, prospective study.

J Asthma Allergy 2018 4;11:225-231. Epub 2018 Sep 4.

Allergy Diagnostic and Clinical Research Unit, Department of Medicine, University of Cape Town Lung Institute, Cape Town, South Africa.

Background: There are few clinical trials that assess the efficacy of antihistamines in very young children. Rupatadine is a second-generation antihistamine indicated for the treatment of allergic rhinitis (AR) and urticaria. In this study, AR symptoms were evaluated before and after daily 1 mg/mL rupatadine oral solution administration in 2-5-year-old children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S164632DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128281PMC
September 2018
19 Reads

Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort.

J Asthma Allergy 2018 31;11:217-224. Epub 2018 Aug 31.

Epidemiology and Research Partnerships, AstraZeneca, Courbevoie, France.

Background And Objective: Benralizumab (Fasenra) has recently been approved as add-on maintenance treatment for adult patients with severe eosinophilic asthma inadequately controlled despite high-dosage inhaled corticosteroids plus long-acting β-agonists. We aimed to identify and describe the clinical characteristics and disease burden of patients with severe, uncontrolled, eosinophilic asthma in France who may be eligible for treatment with benralizumab.

Patients And Methods: This was a retrospective analysis of a prospective, noninterventional, observational study of patients in France enrolled in the Asthma and Bronchial Obstruction Cohort (COBRA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S170866DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124449PMC
August 2018
4 Reads

School-based supervised therapy programs to improve asthma outcomes: current perspectives.

J Asthma Allergy 2018 29;11:205-215. Epub 2018 Aug 29.

Division of Academic General Pediatrics, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA,

Background: Asthma is one of the most common chronic diseases of childhood affecting 6.2 million (8.4%) children (<18 years old) in the USA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S147524DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121747PMC
August 2018
2 Reads

Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study.

J Asthma Allergy 2018 29;11:193-204. Epub 2018 Aug 29.

Medical Evidence and Observational Research, AstraZeneca, Gaithersburg, MD, USA.

Purpose: Prior work suggests a threshold of four courses/year of systemic corticosteroid (SCS) therapy is associated with adverse consequences. The objective of this study was to investigate the onset of adverse outcomes beginning at SCS initiation in a broad asthma population.

Patients And Methods: This historical matched cohort study utilized anonymized, longitudinal medical record data (1984-2017) of patients (≥18 years) with active asthma. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/adverse-outcomes-from-initiation-o
Publisher Site
http://dx.doi.org/10.2147/JAA.S176026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121746PMC
August 2018
9 Reads

Prevalence of allergic sensitization, hay fever, eczema, and asthma in a longitudinal birth cohort.

J Asthma Allergy 2018 13;11:173-180. Epub 2018 Aug 13.

School of Medicine, University of Western Australia, Perth, WA, Australia,

Purpose: The aim of this study was to longitudinally assess the prevalence of allergic sensitization, asthma, eczema and hay fever from infancy to adulthood in a single cohort.

Participants And Methods: This prospective study is based on a longitudinal birth cohort of 253 participants, with respiratory and immunological assessments at 1, 6, 11, 18 and 24 years of age. Subjects were recruited from an urban maternity hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S170285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095121PMC
August 2018
2 Reads

A purinergic P2Y6 receptor agonist prodrug modulates airway inflammation, remodeling, and hyperreactivity in a mouse model of asthma.

J Asthma Allergy 2018 1;11:159-171. Epub 2018 Aug 1.

Department of Pediatrics, Tufts Medical Center, Boston, MA, USA,

Background: Purinergic receptors control cell proliferation, apoptosis, migration, inflammation, and cytokine secretion. Increased expression of specific purinergic receptors is reported in asthma. The role of purinergic P2Y6 receptors (P2Y6R) in asthma is controversial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S151849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078081PMC
August 2018
20 Reads

Economic considerations in the treatment of systemic allergic reactions.

J Asthma Allergy 2018 20;11:153-158. Epub 2018 Jun 20.

Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine.

Epinephrine is a life-saving medication used to treat systemic allergic reactions including anaphylaxis. Epinephrine autoinjectors (EAIs) are expensive and worldwide availability is limited. Epinephrine prefilled syringes and epinephrine kits are potentially lower-cost alternatives to EAIs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S159851DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016598PMC
June 2018
3 Reads

Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities.

J Asthma Allergy 2018 20;11:143-151. Epub 2018 Jun 20.

Division of Allergy and Immunology, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH, USA.

Epinephrine is the only effective treatment for anaphylaxis but studies routinely show underutilization. This is especially troubling given the fact that fatal anaphylaxis has been associated with delayed administration of epinephrine. Many potential barriers exist to the proper use of epinephrine during an anaphylactic reaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S159400DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016581PMC
June 2018
2 Reads

Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers.

J Asthma Allergy 2018 20;11:121-142. Epub 2018 Jun 20.

Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Anaphylaxis is the most serious of all allergic reactions and can be fatal. The diagnosis is frequently delayed, and misdiagnosis often occurs with asthma or urticaria. Biomarkers such as tryptase are not routinely checked, and appropriate treatment with epinephrine is not administered in a majority of cases, increasing the risk of poor outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S159411DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016596PMC
June 2018
35 Reads

Food allergy and anaphylaxis.

J Asthma Allergy 2018 20;11:111-120. Epub 2018 Jun 20.

Division of Clinical Immunology & Allergy, Department of Medicine, Health Sciences Centre, McMaster University, Hamilton, ON, Canada.

Anaphylaxis is a severe and potentially life-threatening allergic reaction. There are numerous potential causes, with food allergy being the leading cause in children and the focus of this review. Most reactions involve an IgE-mediated mechanism, although non-IgE-mediated and nonimmunologic reactions can occur. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/food-allergy-and-anaphylaxis-peer-
Publisher Site
http://dx.doi.org/10.2147/JAA.S162456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016602PMC
June 2018
3 Reads

Anaphylaxis: getting to the point (and price) of diagnosis and treatment.

Authors:
Ronald B Moss

J Asthma Allergy 2018 20;11:109-110. Epub 2018 Jun 20.

Adamis Pharmaceuticals Corporation, San Diego, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S170650DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016614PMC
June 2018
1 Read

Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

J Asthma Allergy 2018 19;11:101-107. Epub 2018 Jun 19.

Pediatric Pulmonology and National CF Center, Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel.

Background: Allergic bronchopulmonary aspergillosis (ABPA) is a condition characterized by a Th2 response, serum eosinophilia, and increased total serum IgE to . ABPA occurs in cystic fibrosis (CF) and asthma. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/omalizumab-in-allergic-bronchopulm
Publisher Site
http://dx.doi.org/10.2147/JAA.S156049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016275PMC
June 2018
14 Reads

Methacholine challenge testing: comparative pharmacology.

J Asthma Allergy 2018 14;11:89-99. Epub 2018 May 14.

Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.

Standardization of the methacholine inhalation challenge, the most common direct bronchoprovocation test, is important. One aspect of standardization is the appropriate washout period for pharmacologic agents which affect the response. This review summarizes the available data on pharmacologic inhibition of the methacholine response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S160607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957064PMC
May 2018
6 Reads

Acute effects of smoke exposure on airway and systemic inflammation in forest firefighters.

J Asthma Allergy 2018 23;11:81-88. Epub 2018 Apr 23.

1 Department of Pulmonary Medicine, "Sotiria" Hospital; Athens Medical School.

Introduction: The aim of this study was to assess respiratory health and airway and systemic inflammation in professional forest firefighters post firefighting.

Methods: A total of 60 firefighters who participated in forest firefighting operations in Greece during 2008 were included in the study. A questionnaire consisting of symptoms and exposure, pulmonary function, atopy, bronchial hyperresponsiveness, and markers of inflammation in induced sputum, serum, and bronchoalveolar lavage (BAL) fluid was assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S136417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922237PMC
April 2018
6 Reads

Both fractional exhaled nitric oxide and sputum eosinophil were associated with uncontrolled asthma.

J Asthma Allergy 2018 10;11:73-79. Epub 2018 Apr 10.

Department of Respiratory Medicine, The Third People's Hospital, Guangzhou Medical College, Huizhou, People's Republic of China.

Background: Sputum eosinophil and fractional exhaled nitric oxide (FeNO), noninvasive biomarkers of local eosinophilic airway inflammation, can be used to assess asthma outcome. Nevertheless, the clinical application of the association between FeNO and sputum eosinophil is controversial. The aim of the study was to investigate the predictive relationship between FeNO and sputum eosinophil in uncontrolled asthmatic patients and the correlation between sputum eosinophil and FeNO in bronchial reversibility and bronchial hyperresponsiveness (BHR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S155379DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901202PMC
April 2018
4 Reads

Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma.

J Asthma Allergy 2018 5;11:63-72. Epub 2018 Apr 5.

AstraZeneca, Gaithersburg, MD, USA.

Background: Patients prefer at-home subcutaneous administration of biologics across different diseases, yet no biologic is approved for at-home use for severe, uncontrolled asthma.

Objective: We assessed at-home functionality, reliability, and performance of an accessorized pre-filled syringe (APFS) for subcutaneous benralizumab administration, an anti-eosinophil monoclonal antibody indicated for add-on maintenance treatment of patients with severe eosinophilic asthma.

Materials And Methods: Patients (N=116) with severe, uncontrolled asthma despite receiving medium- or high-dosage inhaled corticosteroids and long-acting β-agonists received up to 5 APFS-administered subcutaneous doses (Weeks 0, 4, 8, 12, and 16) of benralizumab 30 mg. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S157762DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896651PMC
April 2018
8 Reads

Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history.

J Asthma Allergy 2018 3;11:53-61. Epub 2018 Apr 3.

Division of Allergy and Immunology, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.

Asthma is a heterogeneous syndrome with numerous underlining molecular and inflammatory mechanisms contributing to the wide spectrum of clinical phenotypes. Multiple therapies targeting severe asthma with type 2 (T2) high inflammation are or soon will be available. T2 high inflammation is defined as inflammation associated with atopy or eosinophilia or an increase in cytokines associated with T-helper 2 lymphocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S107982DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892947PMC
April 2018
3 Reads

Current perspectives on tree nut allergy: a review.

J Asthma Allergy 2018 26;11:41-51. Epub 2018 Mar 26.

The Elliot and Roslyn Jaffe Food Allergy Institute, Division of Allergy and Immunology, Kravis Children's Hospital, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Tree nut (TN) allergy is common and often severe. It has become an important health concern as availability and consumption have increased. Prevalence varies by age and geographic region and appears to have increased in children. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S141636DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875412PMC
March 2018
3 Reads

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis.

J Asthma Allergy 2018 23;11:29-39. Epub 2018 Mar 23.

Bausch + Lomb, Irvine, CA, USA.

Background: Bepotastine besilate ophthalmic solution (BBOS) 1.5% is a topical antihistamine for the treatment of ocular itching associated with allergic conjunctivitis (AC). Allergic rhinitis and AC are common comorbid conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S160687DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870655PMC
March 2018
4 Reads

Late-onset asthma: current perspectives.

J Asthma Allergy 2018 9;11:19-27. Epub 2018 Feb 9.

Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.

Because the pathophysiology of asthma has diverse characteristics, to manage the disease effectively, it is important for clinicians to distinguish among the clinical phenotypes. Among them, adult-onset asthma, that is, late-onset asthma (LOA), is increasing because of the aging of the population. The phenotype of LOA is largely divided into two types according to the presence or absence of eosinophilic inflammation, T-helper (Th)2- and non-Th2-associated LOA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S125948DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810515PMC
February 2018
3 Reads

Severe bronchial asthma in children: a review of novel biomarkers used as predictors of the disease.

J Asthma Allergy 2018 15;11:11-18. Epub 2018 Jan 15.

Department of Pediatrics, University of Nigeria Teaching Hospital, Ituku-Ozalla, Nigeria.

Severe asthma or therapy-resistant asthma in children is a heterogeneous disease that affects all age-groups. Given its heterogeneity, precision in diagnosis and treatment has become imperative, in order to achieve better outcomes. If one is thus able to identify specific patient phenotypes and endotypes using the appropriate biomarkers, it will assist in providing the patient with more personalized and appropriate treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S149577DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774744PMC
January 2018
4 Reads

Elevated fractional exhaled nitric oxide and blood eosinophil counts are associated with a 17q21 asthma risk allele in adult subjects.

J Asthma Allergy 2018 19;11:1-9. Epub 2017 Dec 19.

Division of Allergy, Pulmonary and Critical Care, Department of Medicine.

Background And Objectives: Genome-wide association studies identified single-nucleotide polymorphisms (SNPs) at the 17q21 locus conferring increased risk for childhood-onset asthma. Little is known about how these SNPs impact adult asthma patients. We sought to examine an adult population for associations between rs7216389 (17q21-associated SNP) and features of asthma including fractional exhaled nitric oxide (FeNO), eosinophil counts, and age of asthma onset. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S149183DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741070PMC
December 2017
10 Reads

Recovery of hypothalamo-pituitary-adrenal axis suppression during treatment with inhaled corticosteroids for childhood asthma.

J Asthma Allergy 2017 15;10:317-326. Epub 2017 Dec 15.

Department of Endocrinology.

Objective: To describe recovery of adrenal insufficiency in asthmatic children treated with inhaled corticosteroids (ICS) and cortisol replacement therapy.

Design: Retrospective, observational study.

Patients: A total of 113 patients, 74 male; age 10. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S142874DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735982PMC
December 2017
6 Reads

Transplant-acquired food allergy: current perspectives.

J Asthma Allergy 2017 1;10:307-315. Epub 2017 Dec 1.

Division of Allergy and Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Mechanisms that regulate the tolerance to dietary proteins or the loss of this and subsequent development of disease are poorly understood. In food allergy, there is growing awareness of the urgency in understanding these events to aid in the development of next-generation therapies and interventions. This review focuses on the accumulating evidence related to food allergy that develops after transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S136319DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716392PMC
December 2017
4 Reads

Is it severe asthma or asthma with severe comorbidities?

J Asthma Allergy 2017 29;10:303-305. Epub 2017 Nov 29.

Allergy and Clinical Immunology, University of Torino and Mauriziano Hospital.

Severe asthma is defined as asthma that requires treatment with high-dose inhaled corticosteroids (ICSs) plus a second controller and/or systemic corticosteroids to prevent it from becoming uncontrolled or that remains uncontrolled despite this therapy. This definition has limitations: 1) it does not define any biological characteristic that distinguishes severe asthma from asthma in general and 2) it relies on the clinical interpretation of asthma symptoms that are not specific. Actually, wheezing, dyspnea, cough and chest tightness may be caused by the comorbidities (such as rhinosinusitis, obesity and vocal cord dysfunction [VCD]) which are associated with asthma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S150462DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716393PMC
November 2017
8 Reads

Animal models of asthma: utility and limitations.

J Asthma Allergy 2017 7;10:293-301. Epub 2017 Nov 7.

Clinical Immunology and Allergy Division, Department of Internal Medicine, University of São Paulo School of Medicine, São Paulo, Brazil.

Clinical studies in asthma are not able to clear up all aspects of disease pathophysiology. Animal models have been developed to better understand these mechanisms and to evaluate both safety and efficacy of therapies before starting clinical trials. Several species of animals have been used in experimental models of asthma, such as , rats, guinea pigs, cats, dogs, pigs, primates and equines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S121092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683778PMC
November 2017
11 Reads

Study of the clinical and functional characteristics of asthmatic children with obstructive sleep apnea.

J Asthma Allergy 2017 12;10:285-292. Epub 2017 Oct 12.

Biomedical Research Center, Lam Dong Medical College, Dalat, Vietnam.

Background And Objective: The obstructive sleep apnea (OSA) is a common respiratory disorder in children, especially those at preschool and school ages. This study aimed to describe the characteristics of asthmatic children with OSA and the symptoms for a high risk of OSA.

Subjects And Methods: It was a prospective and descriptive study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S147005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644536PMC
October 2017
13 Reads

Differentiating vocal cord dysfunction from asthma.

J Asthma Allergy 2017 12;10:277-283. Epub 2017 Oct 12.

Respiratory Unit, Third Department of Pediatrics, Athens University Medical School, "Attikon" University Hospital, Haidari, Greece.

Vocal cord dysfunction (VCD)-associated symptoms are not rare in pediatric patients. Dyspnea, wheezing, stridor, chest pain or tightness and throat discomfort are the most commonly encountered symptoms. They may occur either at rest or more commonly during exercise in patients with VCD, as well as in asthmatic subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S146007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644529PMC
October 2017
8 Reads

Asthma with bronchial hypersecretion: expression of mucins and toll-like receptors in sputum and blood.

J Asthma Allergy 2017 12;10:269-276. Epub 2017 Oct 12.

Service of Pneumology, Hospital de la Santa Ceu i Sant Pau, Institute of Sant Pau Biomedical Research (IBB Sant Pau), Universitat Autònoma de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES).

Asthma with bronchial hypersecretion is a type of asthma that is poorly studied. Its pathogenesis is not well understood, but is probably related to innate impaired immunity, particularly with toll-like receptors (TLRs) and secretory mucins (MUC).

Objectives: 1) Define the clinical and inflammatory phenotype of asthma with bronchial hypersecretion of mucus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S142200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644553PMC
October 2017
3 Reads

Postpartum airway responsiveness and exacerbation of asthma during pregnancy - a pilot study.

J Asthma Allergy 2017 3;10:261-267. Epub 2017 Oct 3.

Department of Pulmonary Medicine.

Background: Airway responsiveness and inflammation are associated with the clinical manifestations of asthma and the response to pharmacological therapy.

Objective: To investigate if airway responsiveness and inflammatory characteristics are related to asthma exacerbations during pregnancy.

Materials And Methods: In women with asthma who were prescribed controller medication and monitored closely during pregnancy, the risk of exacerbations was analyzed in relation to postpartum measures of fractional exhaled nitric oxide (FNO), skin prick test reactivity, static and dynamic lung volumes, diffusing capacity for carbon monoxide, bronchial responsiveness to inhaled mannitol, and inflammatory characteristics in induced sputum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S137847DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633268PMC
October 2017
10 Reads

Asthma symptoms, mannitol reactivity and exercise-induced bronchoconstriction in adolescent swimmers versus tennis players.

J Asthma Allergy 2017 3;10:249-260. Epub 2017 Oct 3.

Respiratory Medicine and Allergology, Department of Clinical Sciences, Lund, Lund University, Lund.

Background: Strenuous physical activity at an elite level is associated with an increased risk for asthma and, in some sports, also prevalence of allergies. The aim of this study was to investigate the prevalence of asthma and allergy among elite swimmers and tennis players and compare airway hyperreactivity to mannitol and exercise.

Materials And Methods: One hundred and one adolescent swimmers and 86 tennis players answered a questionnaire about respiratory symptoms and allergy and performed mannitol challenge and sport-specific exercise challenge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S134794DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633302PMC
October 2017
14 Reads

Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?

J Asthma Allergy 2017 30;10:237-247. Epub 2017 Aug 30.

Department of Medical Specialties, Pneumology Unit, IRCCS- Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

The increasing understanding of the molecular biology and the etiopathogenetic mechanisms of asthma helps in identification of numerous phenotypes and endotypes, particularly for severe refractory asthma. For a decade, the only available biologic therapy that met the unmet needs of a specific group of patients with severe uncontrolled allergic asthma has been omalizumab. Recently, new biologic therapies with different mechanisms of action and targets have been approved for marketing, such as mepolizumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JAA.S144100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587160PMC
August 2017
12 Reads